154 related articles for article (PubMed ID: 37867386)
21. Clinical Significance of DNA Variants in Chronic Myeloid Neoplasms: A Report of the Association for Molecular Pathology.
McClure RF; Ewalt MD; Crow J; Temple-Smolkin RL; Pullambhatla M; Sargent R; Kim AS
J Mol Diagn; 2018 Nov; 20(6):717-737. PubMed ID: 30138727
[TBL] [Abstract][Full Text] [Related]
22. Epigenetics in Myeloproliferative Neoplasms.
McPherson S; McMullin MF; Mills K
J Cell Mol Med; 2017 Sep; 21(9):1660-1667. PubMed ID: 28677265
[TBL] [Abstract][Full Text] [Related]
23. Clinicopathologic characterisation of myeloid neoplasms with concurrent spliceosome mutations and myeloproliferative-neoplasm-associated mutations.
Liu YC; Illar GM; Bailey NG
J Clin Pathol; 2020 Nov; 73(11):728-736. PubMed ID: 32217616
[TBL] [Abstract][Full Text] [Related]
24. Identification of a HMGA2-EFCAB6 gene rearrangement following next-generation sequencing in a patient with a t(12;22)(q14.3;q13.2) and JAK2V617F-positive myeloproliferative neoplasm.
Martin SE; Sausen M; Joseph A; Kingham BF; Martin ES
Cancer Genet; 2012 Jun; 205(6):295-303. PubMed ID: 22749035
[TBL] [Abstract][Full Text] [Related]
25. Leukemic Transformation of Myeloproliferative Neoplasms: Therapeutic and Genomic Considerations.
Li B; Mascarenhas JO; Rampal RK
Curr Hematol Malig Rep; 2018 Dec; 13(6):588-595. PubMed ID: 30353413
[TBL] [Abstract][Full Text] [Related]
26. Focus on the epigenome in the myeloproliferative neoplasms.
Kim E; Abdel-Wahab O
Hematology Am Soc Hematol Educ Program; 2013; 2013():538-44. PubMed ID: 24319229
[TBL] [Abstract][Full Text] [Related]
27. Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
Patnaik MM; Lasho TL
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):450-459. PubMed ID: 33275756
[TBL] [Abstract][Full Text] [Related]
28. Clinical and genomic characterization of patients diagnosed with the provisional entity acute myeloid leukemia with BCR-ABL1, a Swedish population-based study.
Orsmark-Pietras C; Landberg N; Lorenz F; Uggla B; Höglund M; Lehmann S; Derolf Å; Deneberg S; Antunovic P; Cammenga J; Möllgård L; Wennström L; Lilljebjörn H; Rissler M; Fioretos T; Lazarevic VL
Genes Chromosomes Cancer; 2021 Jun; 60(6):426-433. PubMed ID: 33433047
[TBL] [Abstract][Full Text] [Related]
29. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.
Abdel-Wahab O; Manshouri T; Patel J; Harris K; Yao J; Hedvat C; Heguy A; Bueso-Ramos C; Kantarjian H; Levine RL; Verstovsek S
Cancer Res; 2010 Jan; 70(2):447-52. PubMed ID: 20068184
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive genomic profiling reveals molecular subsets of
Johnson SM; Haberberger J; Galeotti J; Ramkissoon L; Coombs CC; Richardson DR; Foster MC; Duncan D; Montgomery ND; Ferguson NL; Zeidner JF
Leuk Lymphoma; 2024 Feb; 65(2):209-218. PubMed ID: 37921062
[TBL] [Abstract][Full Text] [Related]
31. New mutations and pathogenesis of myeloproliferative neoplasms.
Vainchenker W; Delhommeau F; Constantinescu SN; Bernard OA
Blood; 2011 Aug; 118(7):1723-35. PubMed ID: 21653328
[TBL] [Abstract][Full Text] [Related]
32. Prognostication in Philadelphia Chromosome Negative Myeloproliferative Neoplasms: a Review of the Recent Literature.
Zhou A; Afzal A; Oh ST
Curr Hematol Malig Rep; 2017 Oct; 12(5):397-405. PubMed ID: 28948488
[TBL] [Abstract][Full Text] [Related]
33. A case of a primary myelofibrosis with progression and related literature review of progression phase genetics.
Chen D; Fuda F; Weinberg O
Int J Lab Hematol; 2021 Jul; 43 Suppl 1():78-81. PubMed ID: 34288445
[TBL] [Abstract][Full Text] [Related]
34. Leukemic Transformation in Myeloproliferative Neoplasms: A Literature Review on Risk, Characteristics, and Outcome.
Yogarajah M; Tefferi A
Mayo Clin Proc; 2017 Jul; 92(7):1118-1128. PubMed ID: 28688466
[TBL] [Abstract][Full Text] [Related]
35. Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies.
Stengel A; Baer C; Walter W; Meggendorfer M; Kern W; Haferlach T; Haferlach C
Blood Adv; 2021 Nov; 5(21):4426-4434. PubMed ID: 34570179
[TBL] [Abstract][Full Text] [Related]
36. Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia.
Soverini S; de Benedittis C; Mancini M; Martinelli G
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S120-8. PubMed ID: 26297264
[TBL] [Abstract][Full Text] [Related]
37. Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies.
Passamonti F; Maffioli M; Caramazza D; Cazzola M
Oncotarget; 2011 Jun; 2(6):485-90. PubMed ID: 21646683
[TBL] [Abstract][Full Text] [Related]
38. Molecular Progression of Myeloproliferative and Myelodysplastic/Myeloproliferative Neoplasms: A Study on Sequential Bone Marrow Biopsies.
Brune MM; Rau A; Overkamp M; Flaadt T; Bonzheim I; Schürch CM; Federmann B; Dirnhofer S; Fend F; Tzankov A
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830756
[TBL] [Abstract][Full Text] [Related]
39. Mutations of myelodysplastic syndromes (MDS): An update.
Ganguly BB; Kadam NN
Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
[TBL] [Abstract][Full Text] [Related]
40. The evolving genomic landscape of myeloproliferative neoplasms.
Nangalia J; Green TR
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):287-96. PubMed ID: 25696868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
